Pharmtech Focus: Eyevensys Raises $12M in a Series B Plus Funding Round

The $12M raised in a Series B Plus funding round will support development of Eyevensys’s EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye.